103 related articles for article (PubMed ID: 38723522)
1. The procoagulant signature of cancer cells drives fibrin network formation in tumor microenvironment and impacts its quality. Implications in cancer cell migration and the resistance to anticancer agents.
Tran HCM; Mbemba E; Mourot N; Faltas B; Rousseau A; Lefkou E; Sabbah M; van Dreden P; Gerotziafas G
Thromb Res; 2024 Jun; 238():172-183. PubMed ID: 38723522
[TBL] [Abstract][Full Text] [Related]
2. Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.
Gerotziafas GT; Galea V; Mbemba E; Khaterchi A; Sassi M; Baccouche H; Prengel C; van Dreden P; Hatmi M; Bernaudin JF; Elalamy I
Thromb Res; 2012 Jun; 129(6):779-86. PubMed ID: 21917301
[TBL] [Abstract][Full Text] [Related]
3. Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.
Rousseau A; Larsen AK; Van Dreden P; Sabbah M; Elalamy I; Gerotziafas GT
Int J Oncol; 2017 Dec; 51(6):1747-1756. PubMed ID: 29075790
[TBL] [Abstract][Full Text] [Related]
4. Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.
Rousseau A; Van Dreden P; Khaterchi A; Larsen AK; Elalamy I; Gerotziafas GT
Int J Oncol; 2017 Dec; 51(6):1793-1800. PubMed ID: 29075792
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells.
Xu W; Bae EJ; Lee MK
Int J Nanomedicine; 2018; 13():7549-7563. PubMed ID: 30532538
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells.
AmraneDjedidi R; Rousseau A; Larsen AK; Elalamy I; Van Dreden P; Gerotziafas GT
Thromb Res; 2020 Mar; 187():170-179. PubMed ID: 32006891
[TBL] [Abstract][Full Text] [Related]
7. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
8. SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells.
Zheng X; Wang C; Xing Y; Chen S; Meng T; You H; Ojima I; Dong Y
Int J Oncol; 2017 Mar; 50(3):893-902. PubMed ID: 28197640
[TBL] [Abstract][Full Text] [Related]
9. OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa.
Gerotziafas GT; Rousseau A; van Dreden P; Mbemba E; Gkalea V; Khaterchi A; Larsen A; Elalamy I
Thromb Res; 2016 Apr; 140 Suppl 1():S169. PubMed ID: 27161675
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
[TBL] [Abstract][Full Text] [Related]
11. Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Rousseau A; Van Dreden P; Mbemba E; Elalamy I; Larsen A; Gerotziafas GT
Thromb Res; 2015 Dec; 136(6):1273-9. PubMed ID: 26489727
[TBL] [Abstract][Full Text] [Related]
12. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
Sootichote R; Thuwajit P; Singsuksawat E; Warnnissorn M; Yenchitsomanus PT; Ithimakin S; Chantharasamee J; Thuwajit C
BMC Cancer; 2018 Feb; 18(1):231. PubMed ID: 29486738
[TBL] [Abstract][Full Text] [Related]
13. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
14. Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
Ząbczyk M; Blombäck M; Majewski J; Karkowski G; Wallen HN; Undas A; He S
Thromb Haemost; 2015 Apr; 113(4):851-61. PubMed ID: 25518887
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
16. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells.
Chowdhury P; Nagesh PKB; Hatami E; Wagh S; Dan N; Tripathi MK; Khan S; Hafeez BB; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
J Colloid Interface Sci; 2019 Feb; 535():133-148. PubMed ID: 30292104
[TBL] [Abstract][Full Text] [Related]
17. Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface.
Campbell RA; Overmyer KA; Bagnell CR; Wolberg AS
Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2247-54. PubMed ID: 18974382
[TBL] [Abstract][Full Text] [Related]
18. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional culture system as a model for studying cancer cell invasion capacity and anticancer drug sensitivity.
Doillon CJ; Gagnon E; Paradis R; Koutsilieris M
Anticancer Res; 2004; 24(4):2169-77. PubMed ID: 15330157
[TBL] [Abstract][Full Text] [Related]
20. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Martinez-Outschoorn UE; Goldberg A; Lin Z; Ko YH; Flomenberg N; Wang C; Pavlides S; Pestell RG; Howell A; Sotgia F; Lisanti MP
Cancer Biol Ther; 2011 Nov; 12(10):924-38. PubMed ID: 22041887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
